Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

responsive web design (RWD)

- PMLiVE

GSK granted EC approval for meningococcal disease vaccine Menveo

The fully liquid presentation is designed to simplify the vaccination process

- PMLiVE

Galderma announces positive late-stage results for nemolizumab in prurigo nodularis

The chronic skin condition is estimated to affect up to 181,000 people in the US

- PMLiVE

Seven strategic steps to enhance patient recruitment & retention in your influenza studies

The development of all treatments, including vaccines, is dependent on people taking part in clinical trials but this can be challenging for influenza studies, especially given the typically short patient...

Innovative Trials

- PMLiVE

Health equity: what will you do?

Achieving health equity is a multidimensional challenge

- PMLiVE

AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

More than 52,000 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

BeiGene’s Tevimbra approved by EC for first-line gastric and oesophageal cancer use

Gastric cancer is the fifth leading cause of cancer-related deaths globally and oesophageal cancer is the sixth

- PMLiVE

Sanofi opens €558m modular concept manufacturing facility in Singapore

The facility is designed to enable rapid changes in production capacities across medicines

- PMLiVE

How the ‘five Ps’ can close health equity gaps

Policymakers, payers, providers, patients and pharma are each uniquely able to impact health equity – and together, achieve real progress

- PMLiVE

Novartis’ Kisqali receives EC approval to treat early breast cancer patients

Approximately 70% of breast cancer cases are diagnosed in the early stages of the disease

- PMLiVE

GSK’s linerixibat shows promise in phase 3 primary biliary cholangitis trial

An estimated 510,000 people will be diagnosed with the rare liver disease globally by 2030

- PMLiVE

FDA approves Shorla Oncology’s Imkeldi to treat leukaemia and other cancers

The solution is an advanced liquid formulation of the tyrosine kinase inhibitor imatinib mesylate

- PMLiVE

All hands on deck

We all need to push harder towards environmental sustainability goals

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links